Multisystem inflammatory syndrome in children (MIS-C) is one of several severe complications of COVID-19 seen in children. The United States Center for Disease Control diagnostic guidelines for MIS-C include age <21 years, 24-hour history of fever ≥38.0ºC, severe illness necessitating hospitalization, two or more organ system involvement, laboratory evidence of inflammation, laboratory or epidemiologic evidence of SARS-CoV-2, and a lack of alternative diagnosis. This case report focuses on one patient who met six out of the seven cardinal features of MIS-C but fell outside the average age range. Unfortunately, the patient died from complications of COVID-19. Since our patient had multiple risk factors, including obesity and Hispanic ethnicity the pathogenesis of the disease occurring in our patient was likely identical to that which occurs in MIS-C. Due to a significant chance of mortality in patients with MIS-C and COVID-19, it is important to consider this diagnosis in older adolescents and young adults. This patient’s unfortunate outcome urges prompt greater suspicion for this rare and life-threatening complication, even though this patient is older than the typical MIS-C patient.
| [1] | Dawood, Fatimah S., et al. “Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York.” JAMA pediatrics (2021).View Article PubMed |
| [2] | Viner, Russell M., et al. “Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents.” Archives of disease in childhood 106.8 (2021): 802-807.View Article PubMed |
| [3] | Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021; 4(6): e2116420. |
| [4] | Son, Mary Beth F., and Kevin Friedman. “Coronavirus disease 2019 (COVID-19): Multisystem inflammatory syndrome in children.” Up to Date (2020). |
| [5] | Payne, Amanda B., et al. “Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2.” JAMA network open 4.6 (2021): e2116420-e2116420. |
| [6] | Feldstein, Leora R., et al. “Multisystem inflammatory syndrome in US children and adolescents.” New England Journal of Medicine 383.4 (2020): 334-346. |
| [7] | Steinberg, Eric, Ellsworth Wright, and Beth Kushner. “In young adults with COVID-19, obesity is associated with adverse outcomes.” Western Journal of Emergency Medicine 21. 4 (2020): 752.View Article PubMed |
| [8] | Graff, Kelly, et al. “Risk factors for severe COVID-19 in children.” The Pediatric Infectious Disease Journal 40.4 (2021): e137-e145.View Article PubMed |
| [9] | Radia, Trisha, et al. “Multisystem inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation.” Paediatric respiratory reviews 38 (2021): 51-57.View Article PubMed |
| [10] | Nakra, Natasha A., et al. “Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management.” Children 7.7 (2020): 69.View Article PubMed |
| [11] | Son, Mary Beth F., and Kevin Friedman. “COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis.” Up to Date (2021). |
| [12] | Cattalini, Marco, et al. “Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics.” Italian journal of pediatrics 47.1 (2021): 1-6.View Article PubMed |
| [13] | Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017; 13(4): 851-863.View Article PubMed |